 "EU drug regulator says it is assessing early data from Pfizer Covid vaccine")
The European Union drug regulator said on Monday it had not yet received results from large-scale trials on the Covid vaccines being developed by Pfizer and BioNTech and that it was currently assessing earlier data on the quality of the shot.
The European Medicines Agency (EMA) started a rolling review of data from trials on the vaccine in early October.
“We evaluated the first batch of data on the vaccine, which came from laboratory studies (non-clinical data). The Agency is currently assessing a second batch of data which relate to the quality of the vaccine, including data related to its ingredients and the way it is produced,” it said in a statement.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%